Avidity Biosciences (RNA) AI Stock Analysis

• Market Cap: $11.30B
• Dividend Yield: N/A
• Average Volume (3M): 2.09M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.43
• Revenue Growth: 106.27%
• EPS Growth: -43.90%
• Country: US
• Employees: 391
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 155,149,640
• 10 Day Avg. Volume: 2,820,857
• 30 Day Avg. Volume: 2,094,181
• PEG Ratio: -0.20
• Price to Book (P/B): 5.88
• Price to Sales (P/S): 529.62
• P/FCF Ratio: -14.96
• Enterprise Value/Market Cap: 0.18
• Enterprise Value/Revenue: 106.14
• Enterprise Value/Gross Profit: -16.47
• Enterprise Value/Ebitda: -2.82
• 1Y Price Target: $72.75
• Price Target Upside: -0.10% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $74.00 ▲(1.62% Upside)
• Action: Reiterated Date: 02/28/26
• Date: Action: Reiterated 02/28/26

The score is primarily held back by weak financial performance (rapidly widening losses and accelerating cash burn) and a major corporate event (merger completion with planned Nasdaq delisting). Technicals are moderately supportive, but valuation is not compelling given ongoing unprofitability and no dividend.

Positive Factors

Low-leverage balance sheet

Avidity’s very low debt-to-equity (~0.03) and sizable asset/equity base (~$2.0B assets, ~$1.69B equity) provide durable financial flexibility to fund clinical programs and absorb R&D spend over the next 2–6 months, lowering near-term refinancing risk while programs advance.

Novartis acquisition validates platform

Completion of Novartis’ acquisition confers strategic validation of Avidity’s antibody-oligonucleotide conjugate (AOC) platform. Integration with Novartis brings development, regulatory and commercialization resources that materially lower execution risk and accelerate pathway to potential approval and launch.

Spin-off funds Atrium cardiology portfolio

The carved-out Atrium Therapeutics begins as a funded, independent entity with two precision cardiology candidates and ~$270M cash. This structural separation preserves capital for cardiac programs and clarifies strategic focus, improving runway and execution visibility for those assets.

Negative Factors

Accelerating cash burn

Cash consumption more than doubled year-over-year, indicating materially higher financing needs. Persistent, large negative operating cash flow increases dilution risk, constrains discretionary R&D choices and elevates execution risk if capital access tightens over the medium term.

Very small, volatile revenue and widening losses

Revenue is minimal and inconsistent while losses have more than doubled, reflecting no internal product cashflow to offset R&D spend. This structural mismatch makes the business reliant on external financing, partnerships or parent-company support to sustain development programs long term.

Delisting and loss of public reporting

The completed merger and planned Nasdaq delisting remove regular SEC reporting and public-market liquidity, reducing transparency and access to public capital. This structural change limits independent minority shareholder protections and makes future public financing or market visibility unlikely.

Avidity Biosciences Business Overview & Revenue Model

Company Description

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

How the Company Makes Money

Avidity Biosciences generates revenue through a combination of research and development collaborations, partnerships, and potential product sales. The company often enters into strategic collaborations with larger pharmaceutical companies, which may provide upfront payments, milestone payments upon the achievement of certain development stages, and royalties on future sales of any products that result from these partnerships. Additionally, Avidity may receive funding through government grants and public offerings, as well as through the commercialization of its proprietary therapies once they receive regulatory approval. The success of its revenue model is significantly influenced by the advancement of its product pipeline and the establishment of new partnerships within the biotechnology and pharmaceutical sectors.

Avidity Biosciences Financial Statement Overview

Summary

Strong, low-leverage balance sheet (debt-to-equity ~0.03 and sizable equity base) supports flexibility, but this is outweighed by very small/volatile revenue, sharply widening losses (net loss ~$685M in 2025), and accelerating cash burn (operating cash flow about -$650M in 2025), implying elevated funding and execution risk.

Income Statement

Revenue remains very small and has been volatile (down ~10% in 2025 vs. 2024 after modest growth in prior years). Losses have widened materially: net loss increased to ~$685M in 2025 from ~$322M in 2024, with very negative profitability (2025 net margin ~-36.5% and EBITDA margin ~-39.8%). While this is not unusual for development-stage biotech, the scale of expense growth relative to revenue signals elevated execution and funding risk.

Balance Sheet

The balance sheet is a clear strength: leverage is very low with debt-to-equity around ~0.03 in 2025 (and even lower in 2024), and equity has expanded significantly over time. Total assets ($~2.0B in 2025) and a large equity base ($~1.69B) provide financial flexibility, but persistent losses imply the company will continue relying on its capital base until commercialization ramps.

Cash Flow

Cash burn is heavy and accelerating: operating cash flow fell to about -$650M in 2025 from -$301M in 2024, and free cash flow was about -$664M in 2025. A positive point is that free cash flow broadly tracks net income (free cash flow to net income ~1.02), indicating the loss is largely reflected in cash usage rather than being masked by working-capital timing; however, the magnitude of burn suggests ongoing financing needs if spending remains at current levels.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	18.75M	10.90M	9.56M	9.22M	9.33M
Gross Profit	14.60M	10.90M	7.46M	7.84M	-91.86M
EBITDA	-680.48M	-376.16M	-233.50M	-177.53M	-117.41M
Net Income	-684.63M	-322.30M	-212.22M	-174.00M	-118.01M
Balance Sheet
Total Assets	1.96B	1.56B	628.55M	638.80M	427.58M
Cash, Cash Equivalents and Short-Term Investments	1.70B	1.50B	595.35M	610.73M	405.54M
Total Debt	94.56M	6.80M	9.85M	10.69M	11.73M
Total Liabilities	269.45M	138.94M	127.79M	60.73M	46.15M
Stockholders Equity	1.69B	1.42B	500.76M	578.08M	381.43M
Cash Flow
Free Cash Flow	-663.76M	-307.94M	-123.29M	-139.09M	-98.55M
Operating Cash Flow	-650.44M	-300.87M	-119.06M	-136.27M	-94.81M
Investing Cash Flow	-38.03M	-854.20M	-130.07M	-189.96M	-82.52M
Financing Cash Flow	850.99M	1.19B	93.86M	346.17M	176.32M

Avidity Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 72.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNA, the sentiment is Positive. The current price of 72.82 is below the 20-day moving average (MA) of 72.82, above the 50-day MA of 72.52, and above the 200-day MA of 52.68, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 58.43 is Neutral, neither overbought nor oversold. The STOCH value of 29.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RNA.

Avidity Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PTCT	65 Neutral	$5.64B	8.81	―	―	97.54%	―
IMVT	62 Neutral	$5.64B	-10.34	-69.35%	―	―	-27.70%
RNA	54 Neutral	$11.30B	-14.67	-32.44%	―	106.27%	-43.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RYTM	50 Neutral	$6.33B	-29.83	-244.45%	―	54.92%	28.47%
CRSP	47 Neutral	$5.77B	-9.23	-30.18%	―	-81.10%	-99.21%

Avidity Biosciences Corporate Events

Avidity Biosciences Completes Merger and Plans Nasdaq Delisting

Following the closing of a previously agreed merger, Avidity Biosciences terminated its equity incentive plans, employee stock purchase plan and an August 9, 2024 sales agreement with TD Securities, and on February 27, 2026 notified Nasdaq that it had completed the transaction and would delist its common stock. Trading in Avidity shares, already halted the evening of February 26, 2026, is set to be suspended from Nasdaq on March 2, 2026, after which the company plans to deregister its stock and end its SEC reporting obligations, converting each outstanding share into the right to receive merger consideration and eliminating public stockholder rights.

As a result of the merger, Avidity experienced a change in control and became a wholly owned subsidiary of the acquiring parent, with no further change in control arrangements known to the company. The entire board and all executive officers resigned at the effective time and were replaced by the directors and officers of the merger subsidiary, while Avidity’s certificate of incorporation and bylaws were simultaneously amended and restated to mirror those of the merger vehicle, cementing its transition to a privately controlled entity.

The most recent analyst rating on (RNA) stock is a Hold with a $78.00 price target. To see the full list of analyst forecasts on Avidity Biosciences stock, see the RNA Stock Forecast page.

Avidity Shareholders Approve Novartis Merger and Spin-Off

At a special meeting held virtually on February 26, 2026, Avidity Biosciences stockholders approved the Agreement and Plan of Merger with Novartis AG and the Separation and Distribution Agreement related to the spin-off of assets into Atrium Therapeutics, Inc. Approximately 79.95% of outstanding shares were represented, and the transactions proposal passed with 123,351,048 votes in favor, satisfying the stockholder vote condition for closing the deals.

Stockholders also approved, on a non-binding advisory basis, the merger-related compensation that may be paid to Avidity’s named executive officers in connection with the merger and separation transactions. No other business was conducted at the meeting, and the strong shareholder support clears a key procedural hurdle toward completing the combination with Novartis and the spin-off of Atrium Therapeutics.

The most recent analyst rating on (RNA) stock is a Hold with a $78.00 price target. To see the full list of analyst forecasts on Avidity Biosciences stock, see the RNA Stock Forecast page.

Avidity Biosciences Advances Toward Novartis Merger Completion

On February 23, 2026, Avidity Biosciences, Inc. announced that it would open its special meeting of stockholders scheduled for that day and immediately adjourn it, reconvening on February 26, 2026 via the same virtual link. The adjournment is intended to allow more time to satisfy conditions for the pro rata distribution of all Atrium Therapeutics, Inc. shares to Avidity stockholders, a prerequisite for the company’s proposed merger with Novartis AG.

Avidity said it expected the Atrium Therapeutics distribution to occur on February 26, 2026 and the merger with Novartis to close on February 27, 2026, with both steps still subject to customary closing conditions including shareholder approvals. To facilitate the distribution and a transition of its stock in connection with the merger, Avidity’s shares are set to trade temporarily on the Nasdaq Global Market under the symbol “RNAM,” while previously submitted proxies and the January 29, 2026 record date remain valid for the reconvened meeting.

The most recent analyst rating on (RNA) stock is a Hold with a $72.00 price target. To see the full list of analyst forecasts on Avidity Biosciences stock, see the RNA Stock Forecast page.

Avidity Plans Spin-Off Amid Novartis Acquisition Agreement

On February 2, 2026, Avidity Biosciences announced that its board has set February 12, 2026, as the expected record date for a pro rata spin-off of Atrium Therapeutics (SpinCo), distributing one share of SpinCo common stock for every ten Avidity shares held, in connection with Novartis AG’s proposed acquisition of Avidity and the carve-out of Avidity’s early-stage precision cardiology programs into the new entity. Completion of both the Novartis merger and the SpinCo spin-off remains contingent on customary closing conditions, including shareholder and regulatory approvals, meaning the record date could still change, and leaving investors focused on execution risk, transaction timing and the future alignment of Avidity’s remaining RNA therapeutics portfolio versus the standalone cardiology-focused SpinCo.

The most recent analyst rating on (RNA) stock is a Hold with a $72.00 price target. To see the full list of analyst forecasts on Avidity Biosciences stock, see the RNA Stock Forecast page.

Avidity Biosciences Receives FTC Clearance for Novartis Merger

On October 25, 2025, Avidity Biosciences entered into a merger agreement under which a Novartis wholly owned subsidiary will merge with Avidity, leaving Avidity as an indirect wholly owned subsidiary of Novartis, and on December 14, 2025 the board approved steps to manage tax and compensation consequences tied to that deal. To mitigate potential “excess parachute payment” consequences under Sections 280G and 4999 of the U.S. tax code and preserve corporate tax deductions, the board accelerated into December 2025 the vesting and payment of certain 2025 bonuses and performance stock units that would otherwise have been paid on closing of the merger or in 2026 for selected executives, including specified cash bonuses and large tranches of performance stock units for four named officers, with no duplication of compensation and subject to tax withholding. Each affected executive entered into a clawback agreement requiring repayment of the accelerated amounts if they are terminated for cause or resign without good reason before the date those payments would originally have been made (or, for accelerated PSUs, before December 31, 2029). Separately, following Hart-Scott-Rodino filings on November 21, 2025, the Federal Trade Commission on December 17, 2025 granted early termination of the HSR waiting period for the merger and related spin-off transactions, clearing a key antitrust condition, though completion of the deal still depends on the separation of Atrium Therapeutics (SpinCo) and other customary closing conditions.

The most recent analyst rating on (RNA) stock is a Hold with a $75.00 price target. To see the full list of analyst forecasts on Avidity Biosciences stock, see the RNA Stock Forecast page.